You are here: Industry Insights > AbbVie

News List

AbbVie assumes full development and commercial control of CF programme pharmatimes
October 25, 2018
AbbVie has announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF).
AbbVie inks yet another Humira biosim deal—this time with Novartis—as EU launches near fiercepharma
October 15, 2018
AbbVie has already inked several patent settlements with biosimilar developers looking to take on its megablockbuster Humira, and now the company is back at the deal table with a fourth.
California sues AbbVie over Humira kickbacks pharmaceutical-technology
September 21, 2018
The California Department of Insurance has filed a lawsuit against AbbVie for allegedly giving illegal kickbacks to health-care providers to keep prescribing its rheumatoid arthritis drug Humira.
AbbVie used nurse 'ambassadors' to protect Humira sales fiercepharma
September 19, 2018
In kickbacks case, CA insurance chief says AbbVie used nurse 'ambassadors' to protect Humira sales
AbbVie Announces Patient-Reported Outcomes Data from Risankizumab Studies americanpharmaceuticalreview
September 18, 2018
AbbVie announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor...
With EU salivating after Humira biosims, analysts start questioning AbbVie's optimism fiercepharma
September 17, 2018
Humira biosimilars will hit the European market next month, but AbbVie executives are still soft-pedaling the threat to their top line. CEO Rick Gonzalez and his colleagues say they'll match competitors on price to keep Humira's market-leading position.
AbbVie builds case for potential psoriasis blockbuster risankizumab ahead of regulatory decisions fiercebiotech
September 14, 2018
AbbVie’s patient-reported outcomes cement the impression that risankizumab is more effective than Stelara and Humira.
Gilead, Galapagos’ filgotinib aces first phase 3, suggesting it can compete with AbbVie’s upadacitinib fiercebiotech
September 13, 2018
The placebo-adjusted figures are in line with those generated in late-phase trials of rival JAK drugs.
AbbVie strikes tentative deal to settle 4,000-plus AndroGel lawsuits fiercepharma
September 12, 2018
Lawyers for AbbVie and AndroGel plaintiffs have reached a potential settlement, Judge Matthew Kennelly wrote in a Monday court filing.
Bristol-Myers, AbbVie net FDA 'breakthrough' for myeloma drug Empliciti fiercepharma
August 27, 2018
The myeloma drug Empliciti is currently approved alongside Revlimid and dexamethasone for patients who have already received anywhere from one to three prior treatments.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page